Every material Form 8-K abrdn Life Sciences Investors filed with the SEC in 2013, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
The Board of Trustees of H&Q Life Sciences Investors authorized a renewal of the Fund's share repurchase program, as announced in a March 22, 2013 press release. The renewed program lets the Fund buy back up to 12% of its outstanding common shares in the open market through July 10, 2014, a one-year extension of the current program's July 10, 2013 end date. The Board says the program aims to narrow the discount between the share price and net asset value per share.
Renewed program allows open-market purchases of up to 12% of outstanding common shares.
Renewed program runs for one year, ending July 10, 2014; the current program ends July 10, 2013.
Tekla Capital Management LLC, the Fund's investment adviser, will decide the amount and timing of repurchases.
The filing states there is no assurance of purchases at any specific discount level, amount or date.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every abrdn Life Sciences Investors filing is on SEC EDGAR ↗. 8-K briefs of other companies →